Company Presentation January 2013 - Epigenomics AG
Company Presentation January 2013 - Epigenomics AG
Company Presentation January 2013 - Epigenomics AG
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
CRC Detection in Right and Left Colon (Prof. Béla Mólnar)<br />
� Blinded case control study, 184 study participants,<br />
92 CRC cases (56 left-, 36 right-sided cases) – tested with<br />
gFOBT* and Septin9<br />
� Sensitivity for detection of left- and right-sided cases was<br />
96% and 94% respectively<br />
� Septin9 was confirmed as a highly sensitive biomarker for the detection of CRC in blood<br />
� Septin9 methylation level shows no difference between left and right side colon cancers<br />
12 | <strong>January</strong> <strong>2013</strong><br />
CRC<br />
sensitivity<br />
Left-sided<br />
cancers<br />
Right-sided<br />
cancers<br />
gFOBT* 68.2 83.3 50.0 70.6<br />
Septin9 95.6 96.4 94.4 84.8<br />
* guaiac Fecal Occult Blood Test<br />
Specificity<br />
Plasma Methylated Sept9 Is a Screening Marker in Both Left- and Right-Sided Colon Cancer. Comparison to FOBT and CEA Results Lead Author:<br />
Professor Dr. Kinga Toth from the 2nd Department of Internal Medicine of Semmelweis University in Budapest, Hungary Abstract No. u1895
Change language